\
&
Contact us
\
&
Contact us
Published on | 2 weeks ago
ProgrammesThe Commission has launched BE READY, a new European Partnership for pandemic preparedness. The aim of the partnership is to strengthen the EU's capacity to anticipate, prevent and respond rapidly to epidemics and pandemics. BE READY focuses on advancing research on emerging and re-emerging pathogens and accelerating the development of diagnostics, treatments and vaccines.
The new partnership has already launched its first Joint Transnational Call (JTC 2026) focusing on 'Advancing knoweldge of host and pathogens dynamics to better combat emerging diseases'.
Research Foundation Flanders (FWO) participates in this call. More information on available funding for researchers based in Flanders and on how to apply is available on the FWO website. Deadline for the submission of pre-proposals is 13 April 2026. Questions on available funding by FWO? Contact europe@fwo.be.
More information on the call, its conditions and how to apply is available on the BE READY dedicated webpage. Interested in applying? Rewatch the information webinar here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
